An estimated 20 million people are diagnosed with cancer annually, a number expected to rise to 35 million by 2050, highlighting the urgent need for innovative treatments. Calidi Biotherapeutics Inc. (NYSE American: CLDI) is at the forefront of addressing this challenge with its precision genetic medicine platform. This technology utilizes engineered viruses to deliver potent genetic medicines directly to tumors, including metastatic sites, offering a groundbreaking approach to cancer therapy.
The platform's potential extends beyond cancer, with preliminary assessments exploring its application in autoimmune diseases, marking a significant step forward in treating conditions with large unmet needs. Calidi's efforts place it among leading companies like Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Roche (OTCQX: RHHBY), which are also pioneering advancements in genetic medicines and cancer treatment.
This development is critical as it represents a shift towards more targeted and effective treatments, potentially reducing the global burden of cancer and other serious diseases. The implications for patients, healthcare systems, and the pharmaceutical industry are profound, offering hope for improved outcomes and quality of life for millions worldwide.
